Patent · US Active

Altered OspA of Borrelia burgdorferi

US8992936B2 · kind B2 · utility

0Cited by
14References
6Claims
0Family size

Assignees

Inventors

Key dates

Filing dateJul 17, 2013
Grant dateMar 31, 2015
Priority date
Expiry dateJul 17, 2033

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02A50/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided herein are OspA polypeptides from Lyme Disease-causing Borrelia having certain alteration(s). In one embodiment, the alteration(s) increase the conformational stability of the OspA polypeptide containing the alteration(s) while maintaining at least some of the antigenicity of the corresponding unaltered OspA polypeptide. In another embodiment, the altered OspA polypeptide has reduced cross-reactivity to hLFA-1, as compared to the corresponding unaltered OspA polypeptide.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.